ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 515

Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib

Michael Weinblatt1, Glen Thomson 2, Kun Chen 3, Sebastian Meerwein 4, Casey Schlacher 5 and John Cush 6, 1Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, 2CIADS Research, Winnipeg, Canada, 3AbbVie Inc., North Chicago, 4AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, 5AbbVie Inc., North Chicago, IL, 65Baylor University Medical Center, Dallas

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: RA – Treatments Poster I: Novel Treatments

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, demonstrated efficacy in the SELECT-BEYOND study in patients (pts) with moderate to severe rheumatoid arthritis (RA) on a stable dose of csDMARDs who had inadequate response (IR) or intolerance to bDMARDs,. In this analysis we evaluated clinical responses among pts receiving UPA and placebo (PBO) based on the number and mechanism of action (MOA) of prior bDMARDs.

Methods: 498 pts were randomized to UPA 15mg or UPA 30mg once daily (QD) or PBO for 12 weeks (wks), after which pts on PBO received UPA 15 or 30mg QD from Wk 12 onwards.1 Pts were subgrouped by the number and/or MOA of bDMARD(s) received prior to enrollment: 1) lack of efficacy (LoE) to ≥1 anti-TNF, 2) LoE to an anti-IL-6, and 3) the number of prior bDMARDs (1 vs 2 vs ≥3). ACR20/50/70 responses, DAS28-CRP low disease activity (LDA, ≤3.2), CDAI LDA (≤10), and CDAI remission (≤2.8) were evaluated at Wk 12. The frequency and percentage of treatment-emergent adverse events (TEAE) in each subgroup was assessed over the first 12 wks. Missing values of the efficacy endpoints were imputed using non-responder imputation (NRI). Nominal P-values are reported without multiplicity adjustment.

Results: Overall baseline disease duration was ~13 years. The majority of pts had LoE to ≥1 anti-TNF (449, 90%); 88 (18%) had LoE to an anti-IL-6; 235 (47%), 137(28%), and 125 (25%) had been treated with 1, 2, or ≥3 prior bDMARDs, respectively.1 At Wk 12, clinical responses were numerically, and often statistically, better for pts receiving either dose of UPA vs PBO, irrespective of their prior bDMARD exposure and the number of prior bDMARDs received. As most pts had LoE to ≥1 anti-TNF, responses in this group were comparable to the overall study population (Table 1). Pts with LoE to an anti-IL-6 receiving UPA 15 or 30 mg QD experienced improvements vs PBO, particularly in achieving LDA and remission, although responses in these pts were generally lower compared to the overall study population. As expected, there was a trend towards lower responses as the number of prior bDMARDs increased (Table 2). Responses at Wk 24 were generally consistent with those at Wk 12 (data not shown). TEAEs across the subgroups were consistent with the overall study population (data not shown).

Conclusion: At Wk 12, treatment with UPA at either 15 or 30 mg QD led to significantly better clinical responses vs PBO in this treatment-refractory population, including in pts with LoE to an anti-TNF or an anti-IL-6, and those who had IR/intolerance to 1, 2 or ≥3 prior bDMARDs, with consistent safety profiles as to the overall study population. 


Disclosure: M. Weinblatt, AbbVie, 5, Amgen, 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Can Fite, 4, CanFite, 4, Canfite, 1, Corrona, 5, CORRONA, 5, Crescendo Bioscience, 2, 5, Gilead, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 5, Inmedix, 4, Lilly, 5, Lycera, 4, 5, Lycero, 1, Merck, 5, Novartis, 5, Pfizer, 5, Regeneron, 2, Roche, 5, Samsung, 5, Sanofi, 2, Sanofi-Regeneron, 2, Scipher, 1, 4, 5, Set Point, 5, SetPoint, 5, UCB, 5, Vorso, 4; G. Thomson, AbbVie, 2, Amgen, 5; K. Chen, AbbVie, 3, 4; S. Meerwein, AbbVie, 3, 4, Abbvie Inc, 1, 4; C. Schlacher, AbbVie, 3, 4; J. Cush, AbbVie, 5, Amgen, GSK, Lilly, Merck, Novartis, Pfizer, Sanofi-Aventis, Servier and Roche., 2, Celgene, 5, Janssen, 5, Merck, Pfizer, Sanofi-Aventis, 5, 8, Novartis, 5, Pfizer, 5.

To cite this abstract in AMA style:

Weinblatt M, Thomson G, Chen K, Meerwein S, Schlacher C, Cush J. Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinical-responses-in-patients-with-inadequate-response-to-bdmards-upon-treatment-with-upadacitinib/. Accessed June 25, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-responses-in-patients-with-inadequate-response-to-bdmards-upon-treatment-with-upadacitinib/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies